Delayed Cerebral Ischemia
21
5
8
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.5%
2 terminated out of 21 trials
80.0%
-6.5% vs benchmark
5%
1 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (21)
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage
Cerebrospinal Fluid Hemoglobin to Monitor for Aneurysmal Subarachnoid Hemorrhage Related Secondary Brain Injury
Remote Ischemic Conditioning in Aneurysmal SAH
Epigenome-wide DNA Methylation Profiling in Aneurysmal Subarachnoid Hemorrhage and Delayed Ischemic Neurologic Deficit
Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine
CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage
Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia
Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration
Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)
Swiss SOS MoCA - DCI Study
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
Role of CT Perfusion in Predicting Poor Outcome After Subarachnoid Hemorrhage
Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage
Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage
Bilateral Bispectral Index (BIS) Study